biOasis Technologies Inc Stock Toronto S.E.
Equities
BTI
CA09064N1033
Biotechnology & Medical Research
Sales 2021 | 4.08M 2.97M | Sales 2022 | 37.72K 27.5K | Capitalization | 19.32M 14.08M |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | -2M -1.46M | EV / Sales 2021 | 5.7 x |
Net cash position 2021 | 2.62M 1.91M | Net Debt 2022 | 171K 125K | EV / Sales 2022 | 517 x |
P/E ratio 2021 |
35.1
x | P/E ratio 2022 |
-6.46
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.95% |
Managers | Title | Age | Since |
---|---|---|---|
Deborah Rathjen
CEO | Chief Executive Officer | - | 17-09-20 |
Dave Jenkins
DFI | Director of Finance/CFO | - | 21-06-30 |
Mei Mei Tian
CTO | Chief Tech/Sci/R&D Officer | - | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Hemeon
BRD | Director/Board Member | 59 | - |
David Wurzer
BRD | Director/Board Member | 65 | 18-07-26 |
Deborah Rathjen
CEO | Chief Executive Officer | - | 17-09-20 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+9.45% | 41.68B | |
+46.00% | 41.25B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+1.28% | 12.29B | |
+29.70% | 12.29B | |
+7.78% | 11.15B |